Skip to main content

Discovery DMPK Quick Guide

Guide to Data Interpretation and integration

  • Book
  • © 2022

Overview

  • Highlights assays, parameters to be optimized, candidate properties, and assessment
  • Contains a large amount of reference data that are useful for day-to-day interpretation of ADME studies
  • Multi disciplinary approach
  • 2824 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this book

eBook USD 54.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (7 chapters)

Keywords

About this book

This book is intended for a broad readership, in particular, those working or interested in drug discovery coming from various disciplines such as medicinal chemistry, pharmacology, drug metabolism and pharmacokinetics, bioanalysis, clinical sciences, biochemistry, pharmaceutics, and toxicology.  It provides, for the first time, a completely integrated look at multiple aspects of ADME sciences (absorption, distribution, metabolism, and excretion) in a summary format that is clear, concise, and self-explanatory.  DMPK in Drug Discovery - Guide to Data Interpretation and integration leverages the prior knowledge from the first book that covers the basics of each concept (Drug Metabolism and Pharmacokinetics Quick Guide).  This reference book is meant to be used day to day and provides many useful tables (used for data interpretation), figures, and case studies that can facilitate drug discovery.  The case studies are intended to be short and relevant to the topic discussed and present another dimension to the discussions.

Authors and Affiliations

  • Genentech, Inc., South San Francisco, USA

    S. Cyrus Khojasteh, Donglu Zhang, Cornelis E.C.A. Hop

  • University of British Columbia, Vancouver, Canada

    Harvey Wong

About the authors

S. Cyrus Khojasteh is a Senior Director and Senior Principal Scientist and heads the Biotransformation Function in DMPK Department at Genentech (South San Francisco). He leads the ADME efforts of macrocyclic peptides and microbiome efforts. His biotransformation research focuses on the mechanisms of biotransformation in drug discovery and development, from small molecules, antibody drug conjugates, and macrocyclic peptides. Cyrus received his PhD in medicinal chemistry from the University of Washington under the direction of Professor Sidney D. Nelson.

Harvey Wong is Associate Professor of Pharmacokinetics in the Faculty of Pharmaceutical Sciences at the University of British Columbia. He obtained his BSc in pharmacy and PhD in pharmacokinetics and biopharmaceutics from the University of British Columbia (Canada). Harvey’s expertise is in pharmacokinetics, and modeling and simulation (translational PK/PD analysis, systems pharmacology, and physiologically based pharmacokinetic modeling). He serves on the editorial boards of Biopharmaceutics and Drug Disposition, Xenobiotica, and Clinical and Translational Sciences.


Donglu Zhang is a Senior Fellow in DMPK at Genentech. He is interested in applying drug metabolism studies in drug design and development of both small molecule drugs, protein degraders, and antibody-drug conjugates (ADC). He received the Sir James Black Award for discovery of and original research on Eliquis from the British Pharmacological Society (2018), and the Ondetti and Cushman Award for invention of mass defect filtering method (MDF) from Bristol-Myers Squibb (2007). He serves on editorial boards of Drug Metabolism and Disposition and Xenobiotica.


Cornelis E.C.A. Hop is Vice President at Genentech and supervises the DMPK Department. He leads a team of about 85 scientists involved in acquisition and interpretation of ADME data in support of drug discovery and development ranging from early stage research to NDA and beyond. Before that he was a senior director at Pfizer and a senior research fellow at Merck, and he received his PhD from the University of Utrecht (the Netherlands). He has extensive experience in ADME sciences with a particular focus on PK optimization, human PK prediction, biotransformation, bioanalysis, and the use of in silico approaches in drug discovery.



Bibliographic Information

  • Book Title: Discovery DMPK Quick Guide

  • Book Subtitle: Guide to Data Interpretation and integration

  • Authors: S. Cyrus Khojasteh, Harvey Wong, Donglu Zhang, Cornelis E.C.A. Hop

  • DOI: https://doi.org/10.1007/978-3-031-10691-0

  • Publisher: Springer Cham

  • eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)

  • Copyright Information: Springer Nature Switzerland AG 2022

  • Hardcover ISBN: 978-3-031-10690-3Published: 13 December 2022

  • Softcover ISBN: 978-3-031-10693-4Published: 13 December 2023

  • eBook ISBN: 978-3-031-10691-0Published: 12 December 2022

  • Edition Number: 1

  • Number of Pages: XXI, 228

  • Number of Illustrations: 70 b/w illustrations, 59 illustrations in colour

  • Topics: Pharmaceutical Sciences/Technology, Pharmacy

Publish with us